title: Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study.
abstract: OBJECTIVE
  Our main objective was to investigate the response rate in pretreated patients with small cell lung cancer (SCLC) who received a weekly administration of topotecan and paclitaxel; our secondary objectives were to assess toxicity and survival.
  
  
  METHODS
  Topotecan 1.75 mg/m2 was combined with paclitaxel 70 mg/m2; these cytotoxic agents were administered once every week (day 1) for 3 consecutive weeks (one cycle), and repeated every 28 days (three infusions per cycle) for a minimum of three cycles.
  
  
  RESULTS
  Forty-five patients were enrolled, 41 of whom were evaluable for response and toxicity. The median number of cycles was two (range 1-6). Eleven/forty-one (26.83%) patients responded: one complete response and ten partial responses; the median duration of response was 4 months (range 2-8 months); the median overall survival was 7 months (95% CI: 4.2-9.8). Myelotoxicity was the most common adverse reaction (grade 3 neutropenia in 19.5% of the patients and grade 4 in 7.32%). Non-hematologic toxicities varied from 2.44% to 9.76%. No patient had to stop treatment due to toxicity.
  
  
  CONCLUSIONS
  Topotecan combined with paclitaxel, given on day 1 on a weekly basis, produced a response rate of 26.83% in pretreated patients with SCLC. Myelotoxicity, particularly neutropenia, was the main adverse reaction, but in a minority of patients.
authors.affiliation: First Department of Oncology, Errikos Dunant Hospital, Semitelou 2A, 115 28 Athens, Greece. dr-gps@ath.forthnet.gr
authors.forename: G P
authors.initials: GP
authors.lastname: Stathopoulos
authors.forename: Ch
authors.initials: Ch
authors.lastname: Christodoulou
authors.forename: J
authors.initials: J
authors.lastname: Stathopoulos
authors.forename: D
authors.initials: D
authors.lastname: Skarlos
authors.forename: S K
authors.initials: SK
authors.lastname: Rigatos
authors.forename: Th
authors.initials: T
authors.lastname: Giannakakis
authors.forename: O
authors.initials: O
authors.lastname: Armenaki
authors.forename: D
authors.initials: D
authors.lastname: Antoniou
authors.forename: A
authors.initials: A
authors.lastname: Athanasiadis
authors.forename: P
authors.initials: P
authors.lastname: Giamboudakis
authors.forename: J
authors.initials: J
authors.lastname: Dimitroulis
authors.forename: N
authors.initials: N
authors.lastname: Georgatou
authors.forename: K
authors.initials: K
authors.lastname: Katis
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan; D017239:Paclitaxel